|
| Press Releases |
|
 |
|
| Monday, August 17, 2020 |
|
|
Bayer and Hua Medicine announce commercialization agreement and strategic partnership for investigational first-in-class novel diabetes treatment dorzagliatin in China |
| Bayer and Hua Medicine, a leading innovative drug development company, today announced a commercialization agreement and strategic partnership for dorzagliatin, a novel diabetes treatment, in China. more info >> |
|
| Wednesday, July 1, 2020 |
|
|
Hua Medicine Announces Positive 24-Week Topline Results of Phase III Metformin Combination Trial of Dorzagliatin |
| Hua Medicine today announced the positive 24-week top-line results from HMM0302, a Phase III registration trial in China of its global first-in-class glucokinase activator dorzagliatin add-on to metformin, a first line oral antidiabetic therapy in Type 2 diabetes. more info >> |
|
| Thursday, June 18, 2020 |
|
|
Hua Medicine Successfully Completes SEED (HMM0301), Dorzagliatin Phase III Monotherapy Trial |
| Hua Medicine (the "Company", Stock Code: 2552.HK), a leading innovative drug development company focused on developing novel therapies for the treatment of diabetes, today announced topline results from SEED (also known as HMM0301) more info >> |
|
| Monday, April 27, 2020 |
|
|
Hua Medicine Announces Positive Results in the Combination Study of Dorzagliatin with Empagliflozin (a SGLT-2 inhibitor) |
| Hua Medicine (the "Company", Stock Code: 2552. HK) today announces the positive results of the clinical study HMM0112. more info >> |
|
| Monday, March 16, 2020 |
|
|
Hua Medicine Announces 2019 Annual Results |
| Hua Medicine (the "Company", Stock Code on The Stock Exchange of Hong Kong Limited: 2552.HK), a global innovative drug research and development company focused on novel therapies for the treatment of diabetes, today announces the audited consolidated results of the Company and its subsidiaries for the year ended December 31, 2019. more info >> |
|
| Friday, February 14, 2020 |
|
|
Hua Medicine appoints Dr. Fuxing Tang, a former U.S. FDA Officer, as Chief Technology Officer |
| Hua Medicine, a leading clinical stage biotechnology company based in Shanghai, is pleased to announce that Dr. Fuxing Tang has joined Hua Medicine as Chief Technology Officer, VP of Formulation R&D and Product Development. more info >> |
|
|
|
|
|
|
|
|
 |
| Latest Press Releases |
|
New Report Reveals Key Considerations For Successful Distribution Onboarding
Jul 31, 2025 16:48 HKT/SGT
|
|
|
Over 20 Million Shares Repurchased in Two Days, Shoucheng Holdings Sends a Strong Signal with Decisive Action
Jul 31, 2025 16:43 HKT/SGT
|
|
|
Shoucheng Buys Back 20M Shares in 2 Days, Signals Strong Bet
Jul 31, 2025 16:40 HKT/SGT
|
|
|
Champion REIT Hosts ESG-Themed Event for a Third Year, Redefining Value and Sustainable Future of Commercial Properties Through Innovation 
Jul 31, 2025 16:40 HKT/SGT
|
|
|
TANAKA PRECIOUS METAL GROUP Announces Business Partnership with JEPLAN to Realize a Decarbonized, Circular Society
Jul 31, 2025 15:00 JST
|
|
|
Wintermar Offshore (WINS:JK) Reports 1H2025 Results
Jul 31, 2025 10:56 HKT/SGT
|
|
|
DENSO Announces First Quarter Financial Results
Jul 31, 2025 11:25 JST
|
|
|
Honda Launches All-New Prelude Teaser Page Ahead of Scheduled September 2025 Market Introduction
Jul 31, 2025 11:20 JST
|
|
|
MHI Demonstrates Transport of Relief Supplies in the Event of a Disaster Using Uncrewed Aerial Vehicles Currently in Development
Jul 31, 2025 11:00 JST
|
|
|
Early Alzheimer's Patients Continue to Benefit from Four Years of LEQEMBI(R) (lecanemab-irmb) Therapy New Clinical Data Presented at AAIC
Jul 31, 2025 9:30 JST
|
|
|
New Data Presented at AAIC Demonstrates Investigational LEQEMBI(R) (lecanemab-irmb) 360 mg Subcutaneous Maintenance Dosing Could Offer a New Option for Ongoing Treatment of Early Alzheimer's Disease
Jul 31, 2025 9:20 JST
|
|
|
Two-Year Real-World Study of LEQEMBI(R) in the United States Presented at Alzheimer's Association International Conference (AAIC) 2025
Jul 31, 2025 9:10 JST
|
|
|
HKTDC welcomes the 'Report on Hong Kong's Business Environment' and continues to actively promote Hong Kong's advantages
Jul 30, 2025 22:40 HKT/SGT
|
|
|
Hong Kong Shopping Festival Returns in August with Bigger and Better 2nd Edition
Jul 30, 2025 22:40 HKT/SGT
|
|
|
Naoris Protocol Announces Upcoming TGE for $NAORIS
Jul 30, 2025 22:00 HKT/SGT
|
|
|
|
|
More Press release >> |
|
|
|
|
|
|
|
